• Briacell Therapeutics reported enrollment surpassed 230 patients in its pivotal Phase 3 Bria-ABC trial testing Bria-IMT with an immune checkpoint inhibitor in metastatic breast cancer.
• Interim topline results are scheduled for 2026, with the interim analysis tied to a predefined number of deaths in the study population.
• Management flagged interim overall survival findings as potential support for a future approval filing if results are positive.
• Trial remains under FDA Fast Track designation, supporting an accelerated regulatory path if efficacy is confirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120730PRIMZONEFULLFEED9717977) on May 12, 2026, and is solely responsible for the information contained therein.